Related Experiment Videos
Cancer vaccines: is the future now?
1University of Pennsylvania, School of Medicine, Department of Pathology, Philadelphia, PA 19104, USA. dbweiner@mail.med.upenn.edu
Expert Review of Vaccines
|August 7, 2003
Summary
Cancer immunotherapy shows promise with specific approaches, but challenges remain in translating preclinical success to human trials. Standardization and quantitative immune measurements are key for future advancements in T-cell based therapies.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Cancer immunotherapy is a promising field with specific approaches and antigens, supported by preclinical models.
- Human immune responses to vaccines are nearing thresholds for disease impact, yet few products are in late-stage trials.
- Translating promising technologies from mouse models to human application remains a significant hurdle.
Framework:
- The success of antibody-based therapies suggests that optimized immunization strategies and antigens will significantly impact cancer.
- Improvements in immunogenicity testing in nonhuman primates are needed.
- Standardization through quantitative immune measurement systems, rather than bulk assays, is crucial for data interpretation and vector evaluation.
Implementation:
- Development of class II tetramer technology for tumor antigen evaluation is a welcome advance.
- Flow-based assays for immune evaluation are gaining acceptance.
- Quantitative immune measurements will enable more rapid and intuitive vector evaluation.
Implications:
- While T-cell based cancer immunotherapy faces challenges, its progress mirrors the 20-year development of successful antibody products.
- The next few years are critical for this emerging field, with potential for significant promise and success.
- Continued research and standardization are essential for realizing the full potential of cancer immunotherapy.